AGM Notes, page-5

First 5 Last

Share
Profile

Follow
PapaLaz

584 Posts.

28

29/11/17

17:44

Post #: 29226704
Share
Originally posted by butcherano ↑

Just a few bullet point notes from the AGM.

In general I came out of it with a really positive feel. They’re a really professional outfit, especially Bill Ketelby. He didn’t miss a beat and came across his usual positive and optimistic self.

only around 20 people attended...mix of shareholders and brokers

key message repeated throughout the day was that funding and timeframe for results were putting a hand brake on the share price

at every meeting with financial institutions, brokers or big pharma companies the only questions that kept coming up were “are you fully funded” and “why do we have to wait so long for results”

they’re hoping today’s announcements will resolve that

they’ve received a lot of interest from a broad range of big pharma companies...they’re all supportive of the cortisol approach but need to see more human data before anything would really come out of it

Bill also actually mentioned that a lot of the big US investors might be sitting on the sidelines for the same reason

When Bill was talking about Xanamem he said “it’s apparently disease modifying” but it was a couple of sentences later that he clarified that this was from the animal testing, but read what you want into that. I got the feeling it was a more recent interpretation.

he also spoke about the need to be prepared and plan for a Phase III trial “when we get positive results” but then corrected himself to say “if”....but I liked his optimism

some good questions from the room regarding the future of the trial based on the early results. They seem pretty confident that it won’t have sufficient statistical significance to be a set back. What they’re really hoping to see is a positive trend in the efficacy.

sounds like the diabetes trial is running a bit late because they’re in discussions with the Edinborough University which will result in the uni funding the Phase II trial and we only supply the drug. May also extend to other indications. Sounds good...this trial was going to be quite expensive apparently.

they’re really positive about the diabetes trial because this was where they first began with this drug before they started seeing the cognitive benefit

the guest speakers were very good as well. They’re really on board with the cortisol approach. They’ve only got 3 patients currently completing the trial so no one has actually finished the full 12 weeks yet with them. Really good body language from them but no real feedback to confirm if they’ve seen any noticeable improvements to the patients

in general they’re really excited by the fact that if Xanamem is successful it would be a matter of taking a pill each morning versus other drugs which require intravenous delivery for example

Bill also reinforced that out of all his research he has only ever seen positive articles about the cortisol approach and not one single negative article or anything to indicate that we’re heading in the wrong direction

Cheers,
Butcherano

Expand

Awesome notes really appreciate it @butcherano.
ACW Price at posting: 4.3¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

FEG

China's Xingye snags 19.99% stake in Far East Gold, eyeing latter's Indonesian gold play

DEL

Delorean unlocks $30M through Tanarra finance facility for bioenergy projects

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

SRN

Copper and zinc zone prove exciting news for Surefire close to WA's Yidby

ADH

Adairs MD and CEO steps down after 17 years in company management

There are more pages in this discussion • 2 more messages in this thread...

First 5 Last

Add ACW (ASX) to my watchlist

(20min delay)
Last 3.9¢		Change 0.002(5.41%)		Mkt cap ! $105.7M

Open	High	Low	Value	Volume
3.7¢	4.0¢	3.7¢	$282.2K	7.189M

Buyers (Bids)

No.	Vol.	Price($)
1	107717	3.9¢

Sellers (Offers)

Price($)	Vol.	No.
4.0¢	100000	1

View Market Depth

No.	Vol.	Price($)
1	107717	0.039
5	1862931	0.038
7	587540	0.037
7	1757854	0.036
5	2046500	0.035

Price($)	Vol.	No.
0.040	100000	1
0.041	268263	2
0.042	247609	4
0.043	288344	3
0.044	974735	6

Last trade - 16.10pm 05/09/2024 (20 minute delay)

ACW (ASX) Chart

AGM Notes, page-5

China's Xingye snags 19.99% stake in Far East Gold, eyeing latter's Indonesian gold play

Delorean unlocks $30M through Tanarra finance facility for bioenergy projects

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

Copper and zinc zone prove exciting news for Surefire close to WA's Yidby

Adairs MD and CEO steps down after 17 years in company management

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

AGM Notes, page-5

Top Stories

China's Xingye snags 19.99% stake in Far East Gold, eyeing latter's Indonesian gold play

Delorean unlocks $30M through Tanarra finance facility for bioenergy projects

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

Copper and zinc zone prove exciting news for Surefire close to WA's Yidby

Adairs MD and CEO steps down after 17 years in company management

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News